LinkedIn Image

Novel Strategies in ER-Positive Breast Cancer: An Evolving Cascade of Treatments for Long-Term Disease Control

Meeting Overview

We are pleased to invite you to our satellite symposium, Novel Strategies in ER-Positive Breast Cancer: An Evolving Cascade of Treatments for Long-Term Disease Control, to be held on 5 May 2017 at the IMPAKT 2017 Breast Cancer Conference in Brussels, Belgium.

This interactive program will begin with a discussion of the important cellular pathways in estrogen receptor (ER)–positive breast cancer. Next, expert faculty will focus on new strategies in the treatment of this disease with targeted agents. Throughout the program, panel discussions and interaction with the audience will interest and engage participants.

Agenda

17.00 Welcome, introduction, and “Beat the Expert” clinical quiz
Martine Piccart, MD, PhD
17.10 Endocrine sensitivity and resistance: Are we close to solving the mystery?
Peter Schmid, MD, PhD, FRCP
17.25 Questions from the audience
17.30 Taking the foot off the gas: Clinical consequences of cell cycle inhibition in ER-positive metastatic breast cancer
Angelo Di Leo, MD, PhD
17.45 Questions from the audience
17.50 Signaling pathway inhibition for ER-positive advanced breast cancer: New targets making a difference
Fabrice André, MD, PhD
18.05 Questions from the audience
18.10 The times they are a changin’: New opportunities to improve outcomes in ER-positive advanced breast cancer
Martine Piccart, MD, PhD
18.25 prIME Points™
Martine Piccart, MD, PhD
18.30 Adjourn

Faculty

CHAIR
  • Martine Piccart, MD, PhDJules Bordet Institute
    Brussels, Belgium
FACULTY
  • Fabrice André, MD, PhDGustave Roussy
    Villejuif, France
  • Angelo Di Leo, MD, PhDIstituto Toscano Tumori, Hospital of Prato
    Prato, Italy
  • Peter Schmid, MD, PhD, FRCPBarts Cancer Institute
    Queen Mary University of London
    London, United Kingdom

Target Audience

This educational activity is specifically designed for oncologists, translational scientists, and other healthcare professionals who wish to understand some of the latest developments in treatments for ER-positive breast cancer.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Explain the key mechanisms of endocrine resistance and the emerging strategies to enhance sensitivity to endocrine therapy
  • Examine the role of emerging biomarkers used to inform targeted treatment selection
  • Summarize the clinical application of novel combinations of targeted agents for ER-positive disease
  • Describe the optimum sequence of endocrine therapy approaches across different clinical scenarios

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

Information

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Date and Location

Friday, 5 May 2017
17.00 – 18.30

Room: Silver Hall
SQUARE Brussels Meeting Centre
Glass Entrance
rue Mont des Arts
Brussels, Belgium

Printed Materials

Printed Materials

Provider

This activity is provided by prIME Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Logo_IME_120

Support

This educational activity is supported by a grant from Novartis Oncology.

EFPIA DISCLOSURE CODE

prIME Oncology complies with all EFPIA Disclosure Code reporting requirements.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

I Agree